Poly(lactic-co-glycolic acid) nanoparticles conjugated with CD133 aptamers for targeted salinomycin delivery to CD133+ osteosarcoma cancer stem cells
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cancer stem cells (CSCs) possess the characteristics associated with normal stem cells and are responsible for cancer initiation, recurrence, and metastasis. CD133 is regarded as a CSCs marker of osteosarcoma, which is the most common primary bone malignancy in childhood and adolescence. Salinomycin, a polyether ionophore antibiotic, has been shown to kill various CSCs, including osteosarcoma CSCs. However, salinomycin displayed poor aqueous solubility that hinders its clinical application. The objective of this study was to develop salinomycin-loaded nanoparticles to eliminate CD133(+) osteosarcoma CSCs. METHODS: The salinomycin-loaded PEGylated poly(lactic-co-glycolic acid) nanoparticles (SAL-NP) conjugated with CD133 aptamers (Ap-SAL-NP) were developed by an emulsion/solvent evaporation method, and the targeting and cytotoxicity of Ap-SAL-NP to CD133(+) osteosarcoma CSCs were evaluated. RESULTS: The nanoparticles are of desired particle size (~150 nm), drug encapsulation efficiency (~50%), and drug release profile. After 48 hours treatment of the Saos-2 CD133(+) osteosarcoma cells with drugs formulated in Ap-SAL-NP, SAL-NP, and salinomycin, the concentrations needed to kill 50% of the incubated cells were found to be 2.18, 10.72, and 5.07 μg/mL, respectively, suggesting that Ap-SAL-NP could be 4.92 or 2.33 fold more effective than SAL-NP or salinomycin, respectively. In contrast, Ap-SAL-NP was as effective as SAL-NP, and less effective than salinomycin in Saos-2 CD133(-) cells, suggesting that Ap-SAL-NP possess specific cytotoxicity toward Saos-2 CD133(+) cells. Ap-SAL-NP showed the best therapeutic effect in Saos-2 osteosarcoma xenograft mice, compared with SAL-NP or salinomycin. Significantly, Ap-SAL-NP could selectively kill CD133(+) osteosarcoma CSCs both in vitro and in vivo, as reflected by the tumorsphere formation and proportion of Saos-2 CD133(+) cells. CONCLUSION: Our results suggest that CD133 is a potential target for drug delivery to osteosarcoma CSCs and that it is possible to significantly inhibit the osteosarcoma growth by killing CD133(+) osteosarcoma CSCs. We demonstrated that Ap-SAL-NP have the potential to target and kill CD133(+) osteosarcoma CSCs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699 · cited 3×
“…are especially desirable because PEGylated polymeric nanoparticles have significantly prolonged systemic circulation compared with the nanoparticles without PEG, 21 which greatly improve the passive targeting of nanoparticles to tumor by the enhanced permeability and retention effects.”
Kempf-Bielack, B., Bielack, S. S., Jürgens, H., Branscheid, D., Berdel, W. E., Exner, G. U., Göbel, U., Helmke, K., Jundt, G., Kabisch, H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.063 · Cited by 643 · cited 1×
“In some cases, patients with osteosarcoma will develop a tumor relapse after chemotherapy and surgery.(8,9) This clinical feature leads us to presume that current therapeutic approaches are not efficient to target CSCs in osteosarcoma, according to the concept of CSCs.”
Background
Cited by
Nanomaterials in Targeting Cancer Stem Cells for Cancer Therapy
Qin, W., Huang, G., Chen, Z., & Zhang, Y. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00001 · Cited by 656
Aptamers Chemistry: Chemical Modifications and Conjugation Strategies
Odeh, F., Nsairat, H., Alshaer, W., Ismail, M. A., Esawi, E., Qaqish, B., Bawab, A. A., & Ismail, S. I. (2019) · Molecules · doi:10.3390/molecules25010003 · Cited by 415
A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer
Jain, V., Kumar, H., Anod, H. V., Chand, P., Gupta, N. V., Dey, S., & Kesharwani, S. S. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.07.003 · Cited by 290
The Promise of Nanotechnology in Personalized Medicine
Alghamdi, M. A., Fallica, A. N., Virzì, N., Kesharwani, P., Pittalà, V., & Greish, K. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12050673 · Cited by 284
Aptamer-Functionalized Nanoparticles in Targeted Delivery and Cancer Therapy
Fu, Z., & Xiang, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239123 · Cited by 231
Aptamer-guided nanomedicines for anticancer drug delivery
Alshaer, W., Hillaireau, H., & Fattal, E. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.09.011 · Cited by 187
Exploring the Potential of Nanotherapeutics in Targeting Tumor Microenvironment for Cancer Therapy
Muntimadugu, E., Kommineni, N., & Khan, W. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.05.010 · Cited by 82
Lim, Y. N., Ryu, I. S., Jung, Y.-J., Helmlinger, G., Kim, I., Park, H. W., Kang, H., Lee, J., Lee, H. J., Lee, K. S., et al. (2024) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2024.102340 · Cited by 17
Metadata
- Authors
- Yu, Z., Ni, M., Xiong, M., Zhang, X., Cai, G., Chen, H., & Zeng, Q.
- Venue
- International Journal of Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2015-03
- Volume
- 10
- Pages
- 2537
- ISSN
- 1176-9114 (ISSN-L)
- 1178-2013
- OpenAlex
- W1992388165
- Cited by
- 119
- References
- 2
- FWCI
- 4.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.